Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin/Nepafenac in Bacterial Conjunctivitis
NCT01238783Phase 2Withdrawn
- Sponsor
- Alcon Inc.
- Start
- Jan 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Moxisurge, nepafenac in bacterial conjunctivitis (BC), sponsored by Alcon Inc.. Planned start Jan 2011; status: withdrawn.
02
Drugs
Moxisurgenepafenac
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT01238783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238783.